|
Category:
|
Enzymes ATPases/GTPasesATPase
|
|
Cat.No.
|
Product Name
|
|
2656 |
Concanamycin A
|
| Alternative name(s): |
Folimycin |
|
|
Price and Availability
Click here for full price details of
Concanamycin A
|
|
Chemical Name:
(3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)-18-[(1S,2R,3S)
-3-[(2R,4R,5S,6R)-4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-b
-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-met
hyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methyl
butyl]-9-ethyl-8,10-dihydroxy-3,17- |
|
|
Biological Activity:
Specific inhibitor of V-type (vacuolar) H+-ATPase
that displays > 2000-fold selectivity over other H+-ATPases (IC50
values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type,
F-type, P-type H+-ATPases and porcine P-type Na+,K+-ATPase
respectively). Blocks cell surface expression of virus envelope glycoproteins
without affecting synthesis and exhibits cytotoxicity in several cell lines.
|
Technical Data:
|
|
|
Resources:
|
|
Certificate of Analysis / MSDS:
|
References:
Muroi et al
(1993) Folimycin (Concanamycin A), a specific inhibitor of V-ATPase, blocks
intracellular translocation of the glycoprotein of vesicular stomatitus virus
before arrival to the golgi apparatus. Cell Struct.Function. 18
139. Nishihara et al (1995) Specific inhibitors of vacuolar type
H+-ATPases induce apoptotic cell death. Biochem.Biophy.Res.Comm. 212
255. Hong et al (2006) Nitric oxide production by the
vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin
A and its possible role in apoptosis in RAW 264.7 cells. J.Pharmacol.Exp.Ther. 319
672.
|
|
View related products by Pharmacological Action
or by Research Area
Keywords: Concanamycin A, ATPases / GTPases, H+-ATPase (vacuolar) Inhibitor, Folimycin, Tocris Bioscience
|
|
Literature in this Area Signal Transduction Guide | A complete listing of signal transduction products available from Tocris, including descriptions on selected tools and unit sizes. | | View PDF |
| “I am grateful for your honesty and courtesy. The principles of Tocris are very different to that of your competitors who, in fact, have put our inhibitor on the market without any approval, exhibiting a pirate policy and a total absence of ethics..” Researcher, University of Pisa, Italy |
|
